Inflammation and Atherosclerosis

Why This Matters

Atherosclerosis begins with the retention of ApoB-containing lipoproteins within the arterial wall, but plaque formation and progression are driven by the body's inflammatory response to these retained particles. Lipids initiate the process, while inflammation determines how the lesion evolves over time. Understanding this relationship explains why lowering ApoB remains the cornerstone of prevention, yet anti-inflammatory therapies can provide additional cardiovascular benefit in selected patients.

The Normal Inflammatory Response

Inflammation is an essential component of the immune system.

When tissues are injured or exposed to infection, inflammatory cells remove damaged material and promote healing. Once repair is complete, inflammation normally subsides.

In atherosclerosis, however, the stimulus persists because ApoB-containing lipoproteins continue to enter and remain within the arterial wall. This creates chronic, low-grade inflammation that may continue for decades.

From Lipid Retention to Plaque

Retained lipoproteins undergo chemical modification, including oxidation and aggregation.

These altered particles activate endothelial cells and attract circulating monocytes. After entering the arterial wall, monocytes differentiate into macrophages, ingest modified lipoproteins, and become foam cells.

Macrophages release cytokines, chemokines, and growth factors that recruit additional inflammatory cells and stimulate smooth muscle cell migration and extracellular matrix production. The result is progressive plaque formation.

Chronic Inflammation

Unlike acute inflammation, which resolves after healing, atherosclerotic inflammation persists because the initiating stimulus remains present.

As long as ApoB-containing particles continue to accumulate within the arterial wall, inflammatory pathways remain active. This ongoing cycle contributes to plaque enlargement and may eventually weaken the fibrous cap covering the plaque.

Plaque Rupture

Many cardiovascular events occur not because a plaque is extremely large, but because it becomes unstable.

Inflammatory cells produce enzymes that degrade collagen within the fibrous cap. If the cap ruptures, highly thrombogenic material is exposed to circulating blood, triggering thrombus formation that may abruptly occlude the artery.

This sequence underlies most myocardial infarctions and many ischemic strokes.

Biomarkers of Inflammation

Several laboratory markers provide indirect evidence of systemic inflammation.

High-sensitivity C-reactive protein (hs-CRP) is the most widely studied inflammatory biomarker in cardiovascular medicine. Elevated hs-CRP is associated with increased cardiovascular risk, although it does not identify the location or cause of inflammation.

Treating Inflammation

The most effective way to reduce vascular inflammation is to remove the initiating stimulus.

Lowering ApoB-containing lipoproteins reduces lipid retention within the arterial wall and, consequently, decreases inflammatory activity. This explains why lipid-lowering therapies consistently reduce cardiovascular events.

In selected high-risk patients, anti-inflammatory therapies have demonstrated additional benefit, supporting the concept that inflammation contributes independently to cardiovascular risk. These therapies complement rather than replace aggressive lipid lowering.

The clearest proof came from the CANTOS trial, which tested canakinumab — an antibody that blocks interleukin-1-beta and does not touch cholesterol at all — in patients with a prior heart attack and elevated hs-CRP. It reduced cardiovascular events by about 15 percent compared with placebo, evidence that damping inflammation itself, independent of any lipid change, lowers cardiovascular risk. That result was not a green light for inflammation-targeting drugs generally, though: a similarly designed trial of methotrexate, a cheaper and more familiar anti-inflammatory drug, found no cardiovascular benefit at all, which suggests the specific inflammatory pathway being targeted matters more than "reducing inflammation" as a general strategy. Low-dose colchicine, which works through a different mechanism, produced consistent benefit in two separate trials — COLCOT in patients with a recent heart attack and LoDoCo2 in patients with stable coronary disease — with relative risk reductions in the 25 to 30 percent range, and is now FDA-approved specifically to reduce cardiovascular risk in patients with established atherosclerotic disease. Canakinumab itself was never pursued commercially for cardiovascular disease despite its trial success, largely on cost and a small increase in fatal infections; colchicine, being inexpensive and already approved for other uses, is the anti-inflammatory therapy most likely to appear in practice today.

Clinical Relevance

Inflammation and lipid retention should not be viewed as competing explanations for atherosclerosis.

Instead, they represent sequential components of the same disease process. ApoB-containing lipoproteins initiate the lesion, and inflammation drives its progression.

Optimal prevention therefore requires addressing both lipid burden and the inflammatory response when appropriate — and, as this book's main chapters develop further, insulin resistance itself is one of the most common upstream drivers of that background inflammatory tone.

Clinical Pearls

• Lipid retention initiates atherosclerosis.
• Inflammation promotes plaque progression.
• Chronic vascular inflammation persists because ApoB-containing particles remain within the arterial wall.
• hs-CRP is the most widely used inflammatory biomarker in clinical practice.
• Lowering ApoB reduces both lipid burden and vascular inflammation.

Common Misconceptions

Misconception: Atherosclerosis is purely an inflammatory disease.

Reality: Inflammation is essential to plaque progression, but it is triggered and sustained by the retention of ApoB-containing lipoproteins.

Misconception: Lowering inflammation alone prevents cardiovascular disease.

Reality: Without reducing ApoB-containing particle exposure, the initiating stimulus for vascular inflammation persists.

Misconception: Elevated hs-CRP proves active atherosclerosis.

Reality: hs-CRP reflects systemic inflammation and should always be interpreted within the broader clinical context.

Clinical Bottom Line

Atherosclerosis is neither solely a lipid disorder nor solely an inflammatory disorder. It is a chronic disease in which ApoB-containing lipoproteins initiate arterial injury and inflammation determines plaque progression. Effective prevention requires reducing lifetime exposure to atherogenic particles while recognizing the important role of inflammation in cardiovascular disease.